Watson gets FDA approval for generic Yasmin
MORRISTOWN, N.J. The Food and Drug Administration has approved a generic oral contraceptive made by Watson Pharmaceuticals, the drug maker said Tuesday.
Watson announced the FDA’s approval of Zarah (drospirenone and ethinyl estradiol tablets) in the 3 mg/0.03 mg strength. The drug is a generic version of Bayer’s Yasmin.
Watson said it has started shipping the drug, though Bayer’s patent litigation suit against the company concerning the drug remains pending in the U.S. District Court for the Southern District of New York.
Yasmin and generic versions had sales of around $97 million during the 12 months ended in June, according to IMS Health.
Watson confirms patent challenge for generic Combigan
MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a version of a drug used to treat eye diseases, Watson said Tuesday.
Watson announced that subsidiary Watson Labs had filed for approval of brimonidine tartrate and timolol maleate ophthalmic solution in the 0.2%/0.5% strength. The drug is a generic version of Allergan’s Combigan, used to reduce pressure inside the eye, also known as intraocular pressure, in patients with glaucoma or ocular hypertension for whom current or previous therapies are ineffective.
The drug had sales of around $98 million during the 12-month period ended in July, according to IMS Health.
Allergan filed a patent infringement suit against Watson earlier this month in the U.S. District Court for the Eastern District of Texas in order to prevent Watson from marketing its version of the drug before the expiration of four patents covering Combigan, the last of which expires in January 2023, according to FDA records; the exclusivity period for the drug expires at the end of October of this year. Under the Hatch-Waxman Act, Allergan’s lawsuit places a stay on final FDA approval of Watson’s drug for 2.5 years, or until the two companies resolve the matter before the court.
LifeNexus introduces personal health card
BROOMFIELD, Colo. LifeNexus recently introduced its personal health card, a dual-purpose payment/loyalty card that comes equipped with an embedded microprocessor, the iChip, designed for an individually controlled health platform.
The personal health card can be used to maintain personal health records by securely transferring accurate information at the time and point of need. This will allow professionals access to a patient’s personal health record through card-based consumer authorization, which is both encrypted and password-protected.
The card is EMV-compliant and can be used at the retail pharmacy point of sale for medical/prescription data along with loyalty and/or payment features, LifeNexus noted.
The personal health record also can be directly linked to an unlimited number of disparate databases.
“This platform could offer a retailer a very unique healthcare platform, while enhancing loyalty and potentially prescription adherence,” the company stated. “Pharmacy is quickly becoming the front door to health care, and … an all-encompassing card program like the LifeNexus personal health card can help enhance the retailer’s efforts to be that ‘gateway’ to good health care.”